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1. Introduction
Renal cell cancer is the third most common genitourinary tumour and the seventh most common
cancer. It accounts for about 3% of all malignancies. After prostate cancer and bladder can‐
cer it is the third most common urological tumour. Among urological cancers it shows the
highest mortality [1]. Its incidence has geographic, ethnic and age differences, however over
the last two decades there has been a rising incidence of renal cell carcinoma particularly of
early-stage tumours leading to a paradigm shift in the therapeutic management.
An increased risk of disease is described with a positive family history and the following
diseases: Von Hippel-Lindau (VHL) syndrome, tuberous sclerosis, polycystic renal degener‐
ation, chronic renal insufficiency, dialysis and condition after renal transplantation, arterial
hypertension, adiposity and diabetes mellitus. Other risk factors are drugs (phenacetinabu‐
sus, diuretics) and a number of environmental factors such as asbestos, lead, arsenic, cadmi‐
um and aromatic hydrocarbon compounds. Previous described as typical triad of flank pain,
hematuria and palpable flank tumour (Virchow`s triad) is nowadays rarely seen in far ad‐
vanced tumour stages [2]. The same is true for B symptoms, which is usually a sign of meta‐
stasis already existing.
The increased availability and advances in diagnostic imaging (ultrasound, computed tomog‐
rahy and magnetic resonance imaging) (Fig.1) with an increase in the incidental diagnosis of
renal tumours [3] and an improved understanding of the basic biology of renal cell carcino‐
ma, led in recent years to an improvement in survival rates, however, in approximately one
third of all patients when diagnosed there are metastasis [4] (mainly locoregional lymph nodes,
lung, skeletal system, brain and liver) with a 5-year survival rate of less than 5%.
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Figure 1. Abdominal magnetic resonance imaging (MRI): Renal tumour of the left upper pole: suspected renal cell
carcinoma
Furthermore a third of patients that have been treated for a locally limited renal cell carcino‐
ma (Fig. 2a,b,c) in the course show recurrence or metastasis. A tool to assess the risk of meta‐
stasis after a nephrectomy is the Mayo Scoring System (Tab.1).
Figure 2. (a) Locally limited renal cell carcinoma of the upper pole; (b) Locally limited renal cell carcinoma in the lateral
convexity; (c) Locally limited renal cell carcinoma with suppression of pelvicocaliceal system
Of crucial prognostic importance is therefore the question of the presence of a locally de‐
fined or metastatic renal cell carcinoma with a median survival of about 50% one year after
the diagnosis of metastasis. This underlines the importance of early detection. Because of
lack of radiosensitivity and chemosensitivity of renal cell carcinoma surgical treatment
(nephrectomy or partial nephrectomy) remains the only curative treatment option for locally
confined tumours. Partial nephrectomy/nephron-sparing nephrectomy, minimally invasive
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techniques, energy ablative techniques and active surveillance have been progressively used
as an alternative option towards open radical nephrectomy which was the historical gold
standard approach. Partial nephrectomy has demonstrated an equivalent oncologic outcome
with an improved renal function and reduction of cardiovascular events. Over the past
years laparoscopic and robot-assisted procedures gained in importance showing similar re‐
sults in terms of oncologic control.
Feature Score
Pathologic T stageª
T1a 0
T1b 2
T2 3
T3-4 4
Regional lymph node statusª
pNx/pN0 0
pN1-2 2
Nuclear grading
G1-2 0
G3 1
G4 3
Tumour size
< 10cm 0
> 10cm 1
Histologic tumour necrosis
No 0
Yes 1
ª According to the 2002 American Joint Committee in Cancer staging system
Risk group Score Estimated metastasis-free
survival after 3 years
Estimated metastasis-free survival after 10
years
Low risk 0-2 98% 92.5%
Intermediate risk 3-5 80% 64%
High risk >6 37% 24%
Table 1. Mayo-Scoring-System (Leibovich BC, Blute ML, Cheville JC et al. Prediction of progression after radical
nephrectomy for patients with clear cell carcinoma: a stratification tool for prospective clinical trials. Cancer 2003;
97:1663-1671)
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In metastastic renal cell carcinoma the surgical removal of the primary tumour in the sense
of reducing the tumour burden and metastasis respectively for palliative reasons or as part
of a combined tumour therapy may be required. Through such combined therapy concepts
in some cases significant extensions of survival times can be achieved. Integration of surgery
and systemic therapy is essential in the treatment of metastatic renal cell carcinoma. The ear‐
liest possible diagnosis and careful selection of surgical procedure for each patient is the ba‐
sis with the goal of curation and the best possible quality of life.
2. Therapy for localized renal cell carcinoma
For a long time radical nephrectomy was the standard treatment for normal contralateral re‐
nal function and absence of metastasis. The first successful nephrectomy took place on 2 Au‐
gust 1869 by the Heidelberg surgeon Gustav Simon. In the late 1960s the classic radical
nephrectomy with the removal of kidney and adrenal gland within Gerota`s fascia, includ‐
ing removal of the perirenal adipose capsule, of the proximal ureter and the ipsilateral
lymph nodes with a 5-year overall survival rate of 66% for organ-confined tumours was de‐
scribed by Robson [5], (Tab. 2 and 3).
TNM stageª 5-year cancer-specific survival rate
T1 83%
T2 57%
T3 42%
T4 28%
ª According to the 1997 TNM system (AJCC)
Table 2. 5-year cancer-specific survival after nephrectomy/partial nephrectomy as a function of the 1997 TNM stage
(AJCC) (Tsui KH, Shvarts O, Smith RB et al. Prognostic indicators for renal cell carcinoma: a multivariate analysis of 643
patients using the revised 1997 TNM staging criteria. J Urol 2000; 163:1090-1095)
Robson stage 5-year survival rate
I 75%
II 63%
III 38%
IV 11%
Table 3. 5-year survival rate after nephrectomy, depending on the Robson stage (Guinan PD, Vogelzang NJ, Fremgen
AM et al. Renal cell carcinoma: tumour size, stage and survival. Members of the Cancer Incidence and End Results
Committee. J Urol 1995; 153:901-903)
In the open surgical nephrectomy, the choice of the surgical approach should be taken de‐
pending on the location and size of the tumour as well as the experience of the surgeon. Ba‐
sically the following methods are available: primary retroperitoneal approach to the lumbar
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by use of sub- or intercostal incision, transabdominal or thoracoabdominal. There seems to
be no difference in terms of oncological results.
The laparoscopic nephrectomy (transperitoneal, retroperitoneal or “hand-assisted“) is an‐
other method. This frequently surgical technique is especially used in T1 (up to 7cm tumour
size) and T2 tumours (tumour larger 7cm, limited to the kidney). The surgical steps are basi‐
cally those of the conventional open surgical approach. Comparable oncological results with
open nephrectomy are seen in large tumours as well. [6].
The advantages of laparoscopic nephrectomy are reduction in postoperative pain symptoms
with less pain medication and earlier mobilization. Furthermore faster recovery and better
cosmetic results are mentioned. The frequently discussed risk of implantation metastasis in
the abdominal puncture trocar has only been reported casuistic. A tumour cell spread by the
applied pneumoperitoneum is not known.
The third and most recent method to be mentioned is the robotic-assisted laparoscopic
nephrectomy. Major advantages of this method are the three-dimensional view for the sur‐
geon, up to a 10-fold magnification of the surgical field, a suppression of tremor of the sur‐
geon`s hands through a so-called tremor filter and the free movement of the instruments
which are equivalent to those of the human wrist (so-called “endo wrist instruments”). Ro‐
bot-assisted two approaches are possible: transperitoneal and retroperitoneal approach.
Specific complications of the nephrectomy, regardless of the surgical approach are mainly
injuries to neighbouring organs in particular pleural lesions, spleen, pancreas and duodenal
injuries and bleeding complications. Frequently occurring transient postoperative creatinine
level elevation usually shows a rapid compensation with a healthy contralateral kidney.
As mentioned earlier, in recent years by increasing the availability and development of radi‐
ological examination techniques, there has been an increase of incidentally detected T1 renal
tumours. After the first partial nephrectomy was done in 1887 by Vincenz Czerny at the
University of Heidelberg, it is established today for tumours ≤ 4cm as the gold standard as
well as for tumours up to 7cm in selected patients [7]. Becker et al. showed with the neph‐
rectomy comparable oncologic results and low complication rates in tumours > 4cm [8] or ≥
7cm [9] in selected patients. The 5- year tumour-free survival in this process is over 95%, the
rate of local recurrence is < 1% [10], even though interestingly in section statistics up to 20%
multifocal tumours are detected. A reason for this may lie in a different biological behaviour
of tumours with a different aggressiveness. Whether the multifocal renal cell carcinoma is a
primary multifocal tumour initiation or a secondary intrarenal metastasis is currently un‐
known. Careful preoperative imaging therefore is essential. Aim of the organ-preserving
technique is a complete resection of the tumour with an optimal preserved renal function.
Tumour size 5-year cancer specific survival rate 10-year cancer specific survival rate
< 4cm (T1a) 96% 90%
> 4cm (T1b) 86% 66%
Table 4. 5-year and 10-year cancer-specific survival after partial nephrectomy depending on tumour size (Hafez KS,
Fergany AF, Novick AC. Nephron sparing surgery for localized renal cell carcinoma: impact of tumour size on patient
survival, tumour recurrence and TNM staging. J Urol 1999; 162:1930-1933)
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Regarding the surgical procedure there is a distinction to be made, especially depending on
tumour size and –localization between a number of techniques such as local tumour resec‐
tion (Fig. 3 and 4) in which a safe distance of a few millimeters should be respected, the
poleresection or segmentresection, the heminephrectomy up to nephrectomy with extracor‐
poreal workbench tumour resection and subsequent autotransplantation of the kidney into
the iliac fossa at very large central tumours and imperative implications.
Figure 3. Local resection of a renal tumour
Figure 4. Local resection of a renal tumour (tumour has already been removed)
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When doing a partial nephrectomy a differentiation is made between the most common ex‐
isting elective indications for peripheral small unilateral tumours (≤ 4cm, equivalent to a tu‐
mour stage pT1a or in specialized centres tumours up to 7 cm diameter, equivalent to a
tumour stage pT1b) in a healthy contralateral kidney, the relative indication in impaired re‐
nal function or pre-existing renal insufficiency, synchronous bilateral organ involvement
and genetic predisposition for multiple tumours as well as the absolute/imperative indica‐
tion of an existing solitary kidney (anatomic or functional). Furthermore with this surgical
procedure a distinction is made between a partial nephrectomy without ischemia, in a warm
ischemia in an anticipated ischemic time of < 20 minutes by disconnection of the renal artery
and the renal vein at the renal hilum and partial nephrectomy in cold ischemia (cooling kid‐
ney down to 15-20°C) in an anticipated ischemic time of > 20 minutes by the application of
4°C cold perfusion solution through the renal artery or by surrounding the organ with ice.
Additionally the implementation of so-called renoprotective measures can follow. These in‐
clude intraoperative administration of an ACE inhibitor for the reduction of post-ischemic
vascular resistance and of mannitol 5% 5-10 minutes before clamping and reopening of the
renal artery, with the aim of reducing the intracellular edema and increasing the diuresis
and as needed heparin for the prevention of renal artery thrombosis.
Retrospective studies have shown a benefit for partial nephrectomy compared to a nephrec‐
tomy with T1a tumours, which can be explained mainly by improved renal function with
reduction of cardiovascular events [11]. Also Go et al. have demonstrated in a large prospec‐
tive study that the loss of renal function is associated with an increase in cardiovascular
mortality and shorter life expectancy [12].
Similar to the nephrectomy the partial nephrectomy is an established laparoscopic proce‐
dure performed for the fist time in 1993 by Winfield and Clayman. When performing a lapa‐
roscopic partial nephrectomy the preparation of the renal hilum takes place after colon
mobilization, identification of the ureter as well as the vena cava. Subsequently the excision
of the tumour with scissors usually in warm, rarely performed in cold ischemia takes place.
After attending to the tumour bed with sutures and/or hemostyptics follows an adaptation
of the remaining parenchyma by using a continuous suture. Last is the recovery of the surgi‐
cal specimen in the extraction bag. Similar to the laparoscopic nephrectomy this method
shows the advantages of a lower mean blood loss, lower analgetic requirements postopera‐
tively as well as shorter convalescence and hospitalisation times however at a heightened
risk of postoperative hemorrhage and usually prolonged ischemic times. Regarding the on‐
cological and functional outcomes there are comparable results between open and laparo‐
scopic partial nephrectomy [13].
Similar to the robot-assisted nephrectomy, the laparoscopic robot-assisted procedure also
used with the nephron-sparing surgery represents another possibility of minimally invasive
surgery. After the introduction of the method in 2004 at first primarily small peripherally
located tumours were considered to be particularly suitable for this technique [14]. With in‐
creasing experience the indication was extended to more complex tumours. Excellent results
of robot-assisted surgical technique in relation to more complex lesions, such as centrally lo‐
cated renal tumours or directly at the renal hilum neighbouring tumours are described [15].
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The three-dimensional view and the magnification of the surgical field has the advantage of
a more precise excision of the tumour. In addition, the robotic-assisted partial nephrectomy
has a much shorter learning curve and shorter ischemic times than the conventional laparo‐
scopic procedure. A special technique for the reduction of the ischemic time is the so-called
“sliding clip renorrhaphy“ during renal reconstruction. In this technique a continous ab‐
sorbable suture with clips for securing both ends is used. These clips can then be moved
along the sutures and this way the renal defect can be closed. With this the warm ischemic
time could be reduced significantly [16]. Another method through which the warm ischemic
time can be reduced is the early removal of the vascular clamps, so-called “early unclamp‐
ing”. Few sutures are used in order to avoid more bleeding before removal of the vascular
clamps, to then care for the remaining still bleeding vessels without ischemia [17]. Also the
selective disconnection of the tumour supplying segmental arteries can reduce the ischemic
time, but at an increased risk of injury during preparation of the hilar vessels. While early
experience with robotic partial nephrectomy have demonstrated no advantages of this sur‐
gical method compared to the conventional laparoscopic approach [14], recent work showed
equivalent results in terms of oncologic outcomes for benefits such as a lower intraoperative
blood loss and shorter warm ischemic times compared to those of conventional laparoscopy.
A multicenter study showed comparable results in terms of the following parameters: dura‐
tion of surgery (laparascopic partial nephrectomy 174 min vs. robotic-assisted partial neph‐
rectomy 189 min), cavity opening (54 vs. 47%), R1-status (3.9 vs. 1%) and postoperative
complications (10.2 vs. 8.6%) [18].
The criticism of the robot-assisted partial nephrectomy are essentially two:
1. Dependency of the surgeon on the assistant during surgery
2. High purchase and maintenance costs for the surgical robot
The surgeon sits at the console and does not stand at the operating table, therefore commu‐
nication between him and his assistant surgeon is extremely important, especially during
critical surgical steps such as the setting of vascular clamps and clips.
Comparative  data  on  the  ratio  of  the  costs  for  an  open,  conventional  laparoscopic  and
robotic partial nephrectomy are limited. Mir et al. compared the costs of open, laparoscop‐
ic and robotic partial nephrectomy in 33 patients. They showed laparoscopic partial neph‐
rectomy to be more cost effective than open partial nephrectomy due to a shorter hospital
stay. Moreover they demonstrated that the laparoscopic procedure is more cost effective
compared the  robotic  approach  because  of  lower  instrumentation  costs  [19].  Studies  on
robotic-assisted cystectomy and prostatectomy however showed significantly higher costs
of robotic surgeries [20, 21].
In summary it can be stated that the preservation of functioning renal parenchyma and
therefore a reduction in renal dysfunction is a clear advantage of partial nephrectomy com‐
pared to nephrectomy. The laparoscopic as well as the robotic-assisted partial nephrectomy
in studies with small numbers of patients (Fig. 5 and 6) represent a safe alternative with low
morbidity for selected patients at appropriate centres with special expertise. Specific compli‐
cations with a partial nephrectomy, regardless which type of surgical approach, most likely
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are postoperative hemorrhage and extravasation of urine (urinoma) which can be treated by
a transient ureter splint or nephrostomy. These complications occur more frequently in pa‐
tients with imperative indications than in elective indications.
Figure 5. Robot-assisted laparoscopic partial nephrectomy
Figure 6. Robot-assisted laparoscopic partial nephrectomy (during enucleation of the tumour)
3. Surgical features
Adrenalectomy: After the ipsilateral adrenalectomy over a long period of time on the
grounds of radicalism was seen regradless of size and extent of the renal tumour as essen‐
tial, the indication for performing a routine adrenalectomy during a nephrectomy is not a
standard these days. As an important aspect the fact is that an adrenal tumour rarely grows
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per continuitatem, but most likely it is a sign of haematogenous metastasis with poor prog‐
nosis. On the other side the safety of imaging by using CT is at 97%. The likelihood of adre‐
nal metastasis in small T1 tumours is less than 1% [22]. After Robson in the 1960s described
a survival benefit for patients that had a standard adrenalectomy [5], were not detected in
subsequent studies [23]. The indication for removal of the adrenal gland is given in case of a
very large renal tumour, an upper pole tumour and a suspected metastasis in the adrenal
gland (preoperative imaging studies or intraoperative finding).
Lymphadenectomy: For a long time conducting a regional lymphadenectomy (paraaortic/
paracaval) was an important part of the nephrectomy. The improved survival times when
performing a lymphadenectomy were proven in part by the work of Robson. Especially in
view of conversion of patients to small asymptomatic renal tumours, the removal of the ipsi‐
lateral lymph nodes is critical discussed similarly to the adrenalectomy. Though diagnosti‐
cally useful, the value of the hilar ipsilateral lymphadenectomy due to few studies regarding
their prognostic significance remains unclear. The therapeutic benefit has not been proven.
Interestingly in autopsy studies it was proven that the result of lymph node metastasis usu‐
ally shows an occult distant metastasis.
Renal vein thrombus and vena cava thrombus: A special feature of the renal cell carcinoma
is the tendency of ingrowth into the venous system. A tumour thrombus in the vena cava is
found in about 4-10% of all cases, a tumour thrombus with growth up into the right atrium
in 0.4% of all cases. Surgical removal of the thrombus should be sought in principle. The sur‐
gical procedure must be scheduled in this case depending on the extent of the thrombus.
Level I:Infiltration of the renal vein
Level II:Infiltration of the infrahepatic vena cava
Level III:Infiltration of the intrahepatic vena cava
Level IV:Infiltration of the suprahepatic vena cava
Renal vein thrombi are removed by clamping the junction into the vena cava, thrombi of
the vena cava below the diaphragm by a cavotomy. If there is an expansion beyond the
hepatic hilum the use of a heart-lung machine is necessary. If there is an expansion to the
right atrium the use of extracorporal  circulation is  required.  An important aspect in the
planning and implementation of these procedures is the interdisciplinary collaboration be‐
tween urologists and cardiac surgeons.  The prognosis of  patients with a tumour throm‐
bus after a successfully carried out surgery is not dependent on the size and extent of the
thrombus, but the metastasis stage. After thrombectomy in a non-metastastic stage 5-year
tumour specific survival rates up to nearly 70% can be achieved [24]. However almost half
of all patients with an extensive vena cava thrombus at diagnosis show lymphatic or hae‐
matogenous metastasis.
Bilateral renal tumours: The incidence of synchronous bilateral renal tumours is at 1.6-6%. In
principle a two-stage procedure is desirable, where initially the smaller and unifocal tumour
can be treated in terms of a partial nephrectomy, with the aim to avoid dialysis in case a
subsequent contralateral nephrectomy is required.
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Local recurrence: The discovery of local recurrence in condition after partial nephrectomy
without evidence of systemic metastasis is seen in <3% of all cases. In this case higher local
recurrence rates are seen with imperative indications, which may be explained by a greater
number of advanced tumours. In principal surgical removal should be made after exclusion
of other metastasis.
4. Other techniques
Energy ablative therapy: The energy ablative method is based on tissue destruction by using
cold or heat. Especially cryoablation (CA) and radiofrequency ablation (RFA) are to be men‐
tioned. There are percutaneous and laparoscopic techniques available. Essentially the indi‐
cation for performing the energy ablative method is limited to palliative situations or as an
alternative for high-risk patients with small, conveniently located renal tumours. Potential
benefits represent mainly the reduced morbidity and the possibility of treating multimorbid
patients in an outpatient setting. The problem is, among other things, the increased risk of
local recurrence [25].
LESS/NOTES: After establishing laparoscopic and robot-supported methods now further
developments of the methodology in terms of a reduction of the required trocars (LESS =
Laparoscopic Single Site Surgery) and the use of so-called “natural orifices“ (NOTES = Natu‐
ral Orifice Translumenal Endoscopic Surgery) take place. Concerning this matter so far how‐
ever there are only casuistics and small case series available.
5. Surgical treatment of metastastic renal cell carcinoma
Given the fact that a third of patients who are suffering from a renal cell carcinoma have a
synchronous and another third after curative intent therapy have a metachronous metasta‐
sis, the following shows the possibilities and the importance of surgical therapy for meta‐
stastic renal cell carcinoma.
Basically in metastatic renal cell carcinoma a distinction must be made between the sole pal‐
liative and the cytoreductive nephrectomy. Indication criterias for palliative nephrectomy
for example are conservative uncontrolled pain or recurrent bleeding. In symptomatic mul‐
timorbid patients with a high surgical risk the possibility of a tumour embolization should
be evaluated. Important here is a sufficient analgesic therapy after completion of the proce‐
dure, because severe pain is a common local complication. An impact on the survival rates
cannot be seen with surgical procedure nor with tumour embolization. In the era of immu‐
nochemotherapy it was shown that cytoreductive nephrectomy followed by immunochemo‐
therapy opposed to receiving only medical therapy shows significantly better survival rates
(7.8 months for interferon vs. 13.6 months for nephrectomy plus interferon) [26]. Whether a
nephrectomy in metastatic stage in the post-immunotherapy era is up-to date needs to be
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evaluated. Results of prospective randomized trials for example CARMENA study (“Clini‐
cal Trial to Assess the Importance of Nephrectomy“) are still pending.
With regard to the surgical treatment of metastasis themselves this indication must be made
primarily in response to the location, size and extent of metastasis findings, the symptoms
and the overall situation of the affected patients.
Solitary pulmonary filiae should be checked for resectability. Are there only a few (up to
three) localized metastasis, then a nephrectomy plus complete resection of metastasis can
lead to a significant survival benefit. Basically patients with synchronous pulmonary meta‐
stasis have a significant worse prognosis than those with a metachronous metastasis. If it is
a disseminated metastasis the initiation of a targeted therapy for (long-term) stabilization of
the disease should be discussed with the patient. The basis for this inhibition of tumour
growth is a modification of growth signaling inside the tumour cell and the (neo)angiogene‐
sis. Currently seven substances (in different indications) are available: tyrosine kinase inhib‐
itors such as sunitinib, sorafenib, pazopanib and axitinib, antibody-based therapies such as
bevacizumab plus interferon-alpha and mTOR (“mamillian target of Rapamycin“) inhibitors
as temsirolimus and everolimus. The use of drugs in the adjuvant setting with advanced re‐
nal cell carcinoma with a high risk of disease progression is currently being evaluated in
clinical trials.
In case of hepatic filiae with a median survival rate of 6-18 months the indication for resec‐
tion in case of a solitary metastasis with a diameter <5 cm should be evaluated if liver func‐
tion is intact. It is essential to inform the patient about this procedure`s high morbidity. For
non-resectable liver metastasis it is possible to perform a CT-guided percutaneous radiofre‐
quency induced thermal ablation (RITA).
In the detection of brain metastasis a surgical approach is to be discussed especially with the
onset of neurological symptoms. The indication for resection of metastasis through stereo‐
tactic radiosurgery (GammaKnife, CyberKnife) or radiation therapy is to be weighed indi‐
vidually. When limited in size and number of brain metastasis very good results can be
achieved in this case with regard to the local control of metastasis.
An indication for surgery in bone metastasis may present neurological deficits in a myelon
compression, pain, and fracture risk in instability of the bone. However survival time exten‐
sions are described in an osseous metastasis only in individual cases.
Metachronous adrenal metastasis without evidence of further metastasis should be surgical‐
ly removed.
6. Conclusion
Surgical therapy remains the only curative approach in the treatment of renal cell carcinoma
being resistant opposite radiation and chemotherapy. (Radical) nephrectomy was the stand‐
ard surgical procedure over a long period of time. The spread and further developments of
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imaging diagnostics resulted in an earlier diagnostic of incidentally detected small renal
masses therefore an increase of the performance of nephron-sparing procedures. In the
meantime partial nephrectomy represents the standard surgical technique in pT1a renal cell
carcinomas (size of tumour ≤ 4cm). Over the past years laparoscopic procedures (laparo‐
scopic nephrectomy and laparoscopic partial nephrectomy) showing similar results in con‐
sideration of the oncological outcome compared to open-surgical procedures gained in
importance. Long-term results of the rather new technique of robotic nephrectomy and par‐
tial nephrectomy are encouraging but remain to be seen. LESS (Laparoscopic Single Site Sur‐
gery) and NOTES (Natural Orifice Translumenal Endoscopic Surgery) are first steps
towards modifying established minimal invasive procedures.
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